PMID- 28351584
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20181113
IS  - 1879-0593 (Electronic)
IS  - 1368-8375 (Linking)
VI  - 67
DP  - 2017 Apr
TI  - Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related
      oropharyngeal cancer and antibody trajectories after treatment.
PG  - 77-82
LID - S1368-8375(17)30024-6 [pii]
LID - 10.1016/j.oraloncology.2017.02.004 [doi]
AB  - OBJECTIVES: Despite the fact that HPV-driven oropharyngeal cancer (HPV-OPC) has
      relatively low recurrence rates, intensive post-therapy monitoring remains the
      standard of care. Post-treatment biomarkers are needed to risk stratify HPV-OPC
      patients for more individualized surveillance intensity and which remain at
      higher recurrence risk. MATERIALS AND METHODS: 115 HPV-OPC patients (ascertained 
      by p16 immunohistochemistry and/or in-situ hybridization) from a multicenter
      prospective case study (HOTSPOT) had blood collected at diagnosis, and 64 of
      these also had blood collected at post-treatment follow-up visits for up to two
      years. Samples were centrally tested for antibodies to the L1, E1, E2, E4, E6,
      and E7 proteins of HPV16. RESULTS: At diagnosis, most HPV-OPC cases were
      seropositive to HPV16 E6 (85%). In post therapeutic samples, HPV16 antibody level
      decreased slowly over time, but only 3 (of 51 cases seropositive at enrollment)
      dropped low enough to be classified as seronegative. At 3years after diagnosis,
      cumulative risk of recurrence was 10.2% and 0% in HPV16 E6 seropositive and E6
      seronegative HPV-OPC cases, respectively (p=0.18). Risk of recurrence was
      increased, although not statistically significant, in those with higher HPV16 E6 
      antibody levels at diagnosis (per log antibody level, hazard ratio [HR]=1.81,
      95%CI=0.47-6.92). CONCLUSION: This study confirms the high seroprevalence of HPV 
      oncogenic antibodies at diagnosis of HPV-OPC. HPV16 E6 antibody levels decrease
      after treatment, but most cases remain seropositive for up to two years. HPV16 E6
      antibody levels at diagnosis did not appear to be a strong predictor of
      recurrence.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Zhang, Yuehan
AU  - Zhang Y
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 
      N Wolfe St, Baltimore, MD 21205, USA.
FAU - Waterboer, Tim
AU  - Waterboer T
AD  - German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, 
      Germany.
FAU - Haddad, Robert I
AU  - Haddad RI
AD  - Department of Adult Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave,
      Boston, MA 02215, USA.
FAU - Miles, Brett A
AU  - Miles BA
AD  - Department of Otolaryngology, Icahn School of Medicine at Mount Sinai Medical
      Center, 1 Gustave L. Levy Pl, New York, NY 10029, USA.
FAU - Wentz, Alicia
AU  - Wentz A
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 
      N Wolfe St, Baltimore, MD 21205, USA.
FAU - Gross, Neil D
AU  - Gross ND
AD  - Division of Surgery, Department of Head and Neck Surgery, University of Texas MD 
      Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
FAU - Fakhry, Carole
AU  - Fakhry C
AD  - Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University
      School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA.
FAU - Quon, Harry
AU  - Quon H
AD  - Department of Radiation Oncology, Johns Hopkins University School of Medicine,
      733 N Broadway, Baltimore, MD 21205, USA.
FAU - Lorch, Jochen H
AU  - Lorch JH
AD  - Department of Adult Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave,
      Boston, MA 02215, USA.
FAU - Gourin, Christine G
AU  - Gourin CG
AD  - Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University
      School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA.
FAU - Clayburgh, Daniel
AU  - Clayburgh D
AD  - Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science
      University, 3181 SW Sam Jackson Park Rd, Portland, OH 97239, USA.
FAU - Misiukiewicz, Krzysztof J
AU  - Misiukiewicz KJ
AD  - Tisch Cancer Institute, Head and Neck Oncology Center, Icahn School of Medicine
      at Mount Sinai Medical Center, 1 Gustave L. Levy Pl, New York, NY 10029, USA.
FAU - Richmon, Jeremy D
AU  - Richmon JD
AD  - Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University
      School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA.
FAU - Andersen, Peter E
AU  - Andersen PE
AD  - Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science
      University, 3181 SW Sam Jackson Park Rd, Portland, OH 97239, USA.
FAU - Posner, Marshall R
AU  - Posner MR
AD  - Tisch Cancer Institute, Head and Neck Oncology Center, Icahn School of Medicine
      at Mount Sinai Medical Center, 1 Gustave L. Levy Pl, New York, NY 10029, USA.
FAU - D'Souza, Gypsyamber
AU  - D'Souza G
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 
      N Wolfe St, Baltimore, MD 21205, USA. Electronic address: gdsouza2@jhu.edu.
LA  - eng
GR  - P30 CA006973/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170215
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Alphapapillomavirus/*immunology
MH  - Antibodies, Viral/*immunology
MH  - Female
MH  - Human papillomavirus 16/*immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oropharyngeal Neoplasms/*diagnosis/virology
PMC - PMC5788011
MID - NIHMS935705
OTO - NOTNLM
OT  - *Antibodies
OT  - *E6
OT  - *HPV
OT  - *OPSCC
OT  - *Seroprevalence
EDAT- 2017/03/30 06:00
MHDA- 2018/03/10 06:00
CRDT- 2017/03/30 06:00
PHST- 2016/11/23 00:00 [received]
PHST- 2017/01/26 00:00 [revised]
PHST- 2017/02/06 00:00 [accepted]
PHST- 2017/03/30 06:00 [entrez]
PHST- 2017/03/30 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
AID - S1368-8375(17)30024-6 [pii]
AID - 10.1016/j.oraloncology.2017.02.004 [doi]
PST - ppublish
SO  - Oral Oncol. 2017 Apr;67:77-82. doi: 10.1016/j.oraloncology.2017.02.004. Epub 2017
      Feb 15.